Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: June 25, 2010
Last updated: November 7, 2011
Last verified: November 2011
The purpose of this study is to determine and analyse the incidence, severity, risk factors and routine management of acute drug-induced upper gastrointestinal bleeding (UGIB) in the population of Russian patients

Upper Gastrointestinal Bleeding

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Number and percentage of patients with drug-induced upper gastrointestinal bleeding [ Time Frame: About 1 year ]

Secondary Outcome Measures:
  • Number and percentage of patients with each symptom and each Forrest class of upper gastrointestinal bleeding [ Time Frame: About 1 year ]
  • Number and percentage of patients with concomitant diseases contributing to drug-induced upper gastrointestinal bleeding and those who receive NSAIDs, antiplatelet agents, anticoagulants, steroids or combination therapy [ Time Frame: About 1 year ]
  • Number and percentage of patients with each type of bleeding outcomes who received different types of hemostatic therapy [ Time Frame: About 1 year ]

Enrollment: 300
Study Start Date: June 2010
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Patients with acute upper gastrointestinal bleeding


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary Care Clinic

Inclusion Criteria:

  • Established diagnosis of acute upper gastrointestinal bleeding, confirmed by presence of hematemesis/ coffee ground vomiting, melena, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
  • Written informed consent provided prior the start of participation in the study.

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01155401

Russian Federation
Research Site
Moscow, Russian Federation
Sponsors and Collaborators
Principal Investigator: Boris R Gelfand, Prof Department of the Russian State Medical University
  More Information

Responsible Party: AstraZeneca Identifier: NCT01155401     History of Changes
Other Study ID Numbers: NIS-GRU-NEX-2009/2
Study First Received: June 25, 2010
Last Updated: November 7, 2011

Keywords provided by AstraZeneca:
acute upper gastrointestinal bleeding
patients with drug-induced upper gastrointestinal bleeding
routine management

Additional relevant MeSH terms:
Gastrointestinal Hemorrhage
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases processed this record on April 26, 2017